Avaxia Biologics, Inc.

Louisiana State University and Agricultural & Mechanical College

Immulogic Pharmaceutical Corporation

Embera Neurotherapeutics, Inc.

Tilos Therapeutics, Inc.

Immulogic, Inc.

Merck Sharp + Dohme Corp.

Avaxia Biologies, Incorporated

Immulogic Pharmacuetical Corp.

Barbara S Fox

Malcolm L Gefter

Julia L Greenstein

Mark A Exley

Stephen P Powers

Victoria C Schad

Philip A Swain

Patricia Rao

Nicholas E Goeders

Jessie M English

Thomas J Briner

Stavros Kopsiaftis

Glenn Guerin

Randall Burton

Kenneth J Simon

Xiufeng Song

Renee Moore

Douglas C Stafford

Provided herein are antibodies which bind to latency-associated peptide (LAP) of TGF-&#x3b2;1 and are characterized by particular functional features, such as binding specifically to LAP-TGF&#x3b2;1 on cells but not to LAP-TGF&#x3b2;1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.

Methods of using anti-lap antibodies

Provided herein are anti-LAP antibodies (e.g., recombinant humanized, chimeric, and human anti-LAP antibodies) or antigen binding fragments thereof which have therapeutically beneficial properties, such as binding specifically to LAP-TGF&#x3b2;1 on cells but not to LAP-TGF&#x3b2;1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies or antigen binding fragments in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.

Anti-lap antibody variants

The present invention features, inter alia, pharmaceutically acceptable compositions that include metyrapol as the sole pharmaceutically active agent; compositions that include metyrapol and at least one additional pharmaceutically active agent; compositions in which the agent targeting the HPA axis is, itself, new or modified (e.g., a bi-specific antibody designed to traverse the blood-brain barrier or a known compound redesigned by, for example, conjugation to a substance that traverses the blood-brain barrier); and compositions in which the agent targeting the HPA axis is newly formulated in such a way that it fails to significantly inhibit cortisol production in the adrenal gland. For example, the composition can be formulated to include a dosage that is too low to reduce plasma cortisol levels or formulated to preferentially affect the skin.

Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease

In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. Antibodies are described with increased stability within the environment of the digestive tract. Antibodies are described with enhanced permeability to a compromised digestive tract.

Compositions comprising TNF-specific antibodies for oral delivery and methods of use thereof to treat inflammatory bowel disease

Compositions for the treatment of addiction, psychiatric disorders, and neurodegenerative disease

The present invention includes a pharmaceutical compositions and methods for treating diseases associated with gluten intolerance in a patient, comprising: administering to the patient an effective amount of an antibody having specific activity against gluten or gluten-derived peptides. Such diseases include, for example, celiac disease and dermatitis herpetiformis.

Antibody therapy for treatment of diseases associated with gluten intolerance

Compositions comprising TNF-specific antibodies for oral delivery

The present invention provides pharmaceutical compositions formulated for direct delivery to the GI tract of a patient comprising an antibody specific for a target apical intestinal receptor. The present invention further provides methods of treating diseases and conditions in a patient comprising administering directly to the GI tract of the patient, compositions of the present invention wherein modulation of the target apical intestinal receptor by the antibody treats the condition.

Antibodies to apical intestinal receptors and methods of treating metabolic disease

Methods of treating mucositis using anti-TNF antibodies

Antibody therapy for modulating function of intestinal receptors and methods of treating diabetes and obesity

Methods of using anti-TNF antibodies for treating radiation damage to the digestive tract

Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo are disclosed. Methods of preparing the hapten-carrier conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.

Hapten-carrier conjugates for use in drug-abuse therapy and methods for

Hapten-carrier conjugates capable of eliciting anti hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Anti-hapten antibodies elicited compete with free hapten upon subsequent challenge of a vaccinated individual. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.

Growing community of inventors

Wayland, MA, United States of America

Barbara S Fox